Spontaneous Pneumomediastinum Associated with Semaglutide Therapy: A Case Report.
Case Rep Gastroenterol · 2026
Last updated 2026-08-28| Journal | Case Rep Gastroenterol, 2026 |
|---|---|
| Citations | 0 |
| Molecules | semaglutide |
Abstract
INTRODUCTION: The seemingly harmless side effects of semaglutide, such as vomiting, may rarely lead to serious complications. This case is unique in highlighting spontaneous pneumomediastinum (SPM) as a potential consequence of unsupervised semaglutide use, adding new insight to the literature on the safety profile of weight-loss medications.
CASE PRESENTATION: We report the case of a 26-year-old woman who developed SPM shortly after the self-administered use of semaglutide purchased online for weight loss. The patient presented with vomiting, chest and neck pain, and progressive facial swelling. Imaging revealed extensive pneumomediastinum and cervicothoracic emphysema. Oesophago-gastro-duodenoscopy was performed to rule out oesophageal perforation and showed no abnormalities. The patient was managed conservatively with spontaneous recovery.
CONCLUSION: This case highlights the importance of distinguishing SPM from life-threatening conditions such as Boerhaave's syndrome and raises concerns regarding the unsupervised use of injectable weight-loss medications, emphasizing the need for patient education and careful monitoring.
Verbatim abstract via PubMed 42291462 ↗
Related research
- Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes.
- Once-Weekly Semaglutide in Adults with Overweight or Obesity.
- Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes.
- A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis.
- Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes.
- Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes.
- Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes.
- Semaglutide in Patients with Heart Failure with Preserved Ejection Fraction and Obesity.